VIFN.SW - Vifor Pharma AG

Swiss - Swiss Delayed Price. Currency in CHF

Vifor Pharma AG

Flughofstrasse 61
Glattbrugg
Zurich 8152
Switzerland
41 58 851 80 00
http://www.viforpharma.com

SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees2,764

Key Executives

NameTitlePayExercisedYear Born
Mr. Etienne JornodExec. Chairman4.5MN/A1953
Mr. Stefan SchulzePres of the Exec. Committee & COO1.53MN/A1965
Mr. Colin BondChief Financial OfficerN/AN/A1961
Dr. Dirk SchraderHead of Global Technical OperationsN/AN/AN/A
Mr. Alex SigalasHead of Fin., IT & Admin.N/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CHF.

Description

Vifor Pharma AG researches, develops, produces, and markets pharmaceutical products in Switzerland, Europe, the United States, and internationally. The company offers products that include Ferinject/Injectafer, a solution of ferric carboxymaltose used in the intravenous treatment of iron deficiency; Mircera, a long-acting erythropoiesis-stimulating agent for the treatment of symptomatic anaemia associated with the chronic kidney disease (CKD); and Venofer, a solution for iron sucrose used in the intravenous treatment of iron deficiency. It also provides products, such as Retacrit, an injection for the treatment of anaemia associated with CKD, renal failure, and chemotherapy-induced anaemia; Velphoro, a non-calcium, iron-based, chewable phosphate binder to control the phosphate levels in the blood of adults with CKD; and Veltassa, a sodium-free potassium binder in the treatment of hyperkalaemia in adult patients. In addition, the company offers products that include Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman; Broncho-Vaxom, a treatment and preventive for recurrent respiratory infections; Uro-Vaxom, a treatment and preventive for recurrent urinary tract infections; Doxium, an oral treatment for diabetic retinopathy and haemorrhoidal syndrome; and Uro-Vaxom for the treatment and preventive for recurrent urinary tract infections. Further, its development stage products include VIT-2763, CR845, CCX140, Avacopan, and Vadadustat, as well as Rayaldee, a product in pre-commercial stage. The company was formerly known as Galenica AG and changed its name to Vifor Pharma AG in April 2017. Vifor Pharma AG was founded in 1872 and is headquartered in Zurich, Switzerland.

Corporate Governance

Vifor Pharma AG’s ISS Governance QualityScore as of October 4, 2019 is 3. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 1; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.